Compare KNDI & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNDI | JSPR |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.8M | 48.1M |
| IPO Year | N/A | N/A |
| Metric | KNDI | JSPR |
|---|---|---|
| Price | $0.83 | $1.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $21.44 |
| AVG Volume (30 Days) | 234.7K | ★ 4.0M |
| Earning Date | 03-13-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $104,035,613.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.80 | $1.39 |
| 52 Week High | $1.81 | $22.99 |
| Indicator | KNDI | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 36.61 | 47.03 |
| Support Level | $0.80 | $1.61 |
| Resistance Level | $1.11 | $1.96 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 12.19 | 46.25 |
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.